NCT05850637
Evaluate the Effectiveness and Toxicity of Adjuvant Ultra-hypofractionated Radiotherapy for Breast Cancer
Phase II Study to Evaluate the Effectiveness and Toxicity of Adjuvant Ultra-hypofractionated Radiotherapy for the Treatment of Early and Locally Advanced Breast Cancer
Prevent Senior Institute·Phase 2·ClinicalTrials.gov·radiationCompleted
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Breast Cancer Female
- Drug/Device/Intervention
- adjuvant ultra-hypofractionated radiotherapy
- Study type
- Interventional
- Intervention type
- radiation
Sponsor & location
- Primary sponsor
- Prevent Senior Institute
- Location
- São Paulo, Brazil
Timeline & enrollment
- Phase
- Phase 2
- Start date
- Jan 30, 2019
- End date
- Apr 01, 2023
- Enrollment
- 60 participants
Primary outcome
Acute toxicity,Late toxicity
Summary
Prospective phase 2 study to evaluate the safety and efficacy of ultra-hypofractionated
 adjuvant radiotherapy in 5 fractions of 5.7 Gy in patients aged over 65 years.
ICD-10 classifications
Malignant neoplasm: Breast, unspecifiedMalignant neoplasm of breastMalignant neoplasm of breastCarcinoma in situ of breast, unspecifiedPersonal history of malignant neoplasm of breast
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT05850637
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT05850637 through Pure Global AI's free database. This Phase 2 trial is sponsored by Prevent Senior Institute and is currently Completed. The study focuses on Breast Cancer Female. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.